Multimodality treatment in immunocompromised patients with severe COVID ‐19: the role of IL ‐6 inhibitor, intravenous immunoglobulin, and haemoperfusionCase Report Published on 2021-03-072022-10-29 Journal: Respirology Case Reports [Category] COVID-19, [키워드] administration adverse event alleviate Clinical efficacy Clinical improvement Corticosteroids COVD‐19 COVID COVID‐19 COVID‐19 infection CRS Cytokine release syndrome discharge haemoperfusion Host Immunocompromised Immunocompromised patient Inflammation Inflammatory inhibitor Intravenous immunoglobulin IVIG knowledge mechanical ventilation multimodality Multiple outcome PaO Patient profiles Research SARS‐CoV‐2 severe coronavirus disease stability survived syndrome therapeutic Therapies therapy Tocilizumab treated Treatment [DOI] 10.1002/rcr2.733 PMC 바로가기 [Article Type] Case Report
Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapyCOVID-19 기간 동안 만성 염증성 탈수초성 다발성 신경근신경병증에서 IVIg 요법 재평가: 만성 유지 요법의 필요성을 확인할 기회Article Published on 2021-03-012022-09-12 Journal: Neurological Sciences [Category] SARS, 진단, [키워드] acute respiratory syndrome administration analyzed caused CIDP Clinical deterioration COVID-19 demonstrated Follow-up Health health facilities immunotherapies increased risk Inflammatory IVIG Novel coronavirus outbreak pandemic Patient protective role raised repeated reported risk SARS-CoV-2 SCIg. selected the patient therapy treated Treatment [DOI] 10.1007/s10072-020-04983-5 PMC 바로가기 [Article Type] Article
Immune reactivity during COVID-19: Implications for treatmentCOVID-19 동안의 면역 반응성: 치료에 대한 시사점Review Published on 2021-03-012022-09-11 Journal: Immunology letters [Category] MERS, SARS, 바이오마커, 신약개발, 임상, 진단, 치료법, [키워드] acute respiratory distress acute respiratory distress syndrome affected Antigen appear ARDS best C reactive protein cardiovascular comorbidities cardiovascular comorbidity CD19 cells characterized clinical Clinical symptoms clinical trial clinical trials Coagulopathy contribute convalescent plasma Corticosteroids cough COVID-19 COVID-19 patients Critical CRP Cytokine storm D-dimer disease drug therapy dysregulation Eosinopenia expression fatigue Fever focus helping hematological hematological parameter HLA-DR Host immune response human leukocyte antigen IL-6 IL-6 receptor immune immune dysregulation immune reactivity immune response Immunoglobulin immunological immunological reactivity immunosenescence Immunotherapy in-hospital mortality include Inflammatory response Intravenous immunoglobulin intubation IVIG Laboratory laboratory findings laboratory indexes. lead leukocyte Lymphocytes lymphopenia Macrophage macrophage activation syndrome Mild natural killer occur pathogenic mechanism pathogenic mechanisms Patient patients with COVID-19 predict procalcitonin prognostic biomarker Prognostic biomarkers Prognostic value receptor antagonist reduced reduction respiratory distress Respiratory distress syndrome SARS-CoV-2 severe COVID-19 severity severity of illness symptoms of COVID-19 syndrome T cell T cell response target Therapeutic strategies therapy Tocilizumab trajectory Treatment [DOI] 10.1016/j.imlet.2021.01.001 PMC 바로가기 [Article Type] Review
Treatment of a case of COVID-19 by intravenous immunoglobulin정맥 면역 글로불린에 의한 COVID-19 사례의 치료Case Reports Published on 2021-03-012022-09-11 Journal: Journal of global antimicrobial resistance [Category] MERS, SARS, 진단, 치료법, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus-2 administration conditions coronavirus COVID-19 deficiency immune Immune deficiencies Immunoglobulin Infection Intravenous immunoglobulin IVIG life-threatening Patient positive-sense single-stranded RNA Prevent respiratory RNA virus SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome coronavirus-2 severe COVID-19 specific treatment therapy today treated Treatment virus [DOI] 10.1016/j.jgar.2020.12.003 PMC 바로가기 [Article Type] Case Reports
Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trialSARS-CoV-2 감염과 관련된 급성 호흡 곤란 증후군에 대한 다가 면역글로불린의 조기 치료 효과(ICAR 시험): 무작위 대조 시험을 위한 연구 프로토콜Study Protocol Published on 2021-02-282022-09-01 Journal: Trials [Category] MERS, 임상, 진단, [키워드] 1:1 90% power activities activity acute respiratory distress acute respiratory distress syndrome administration adverse event Alpha ARDS assessment chloride coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 daily living defined died double-blind early treatment Effect effect size Efficacy and safety EudraCT evaluate evaluate the effect failure France functional GRADE grade 3 Hospital stay Hospitalized ICU Immunoglobulin immunomodulatory increase in intensive care intensive care unit Intravenous immunoglobulin IVIG Lung injury mechanical ventilation morbidity mortality rate multicenter Occurrence Organ failure outcome parallel group participant Patient pharmacological treatment placebo group Polyvalent immunoglobulin Primary outcome Randomized Randomized controlled trial receive reduction in respiratory distress SARS-CoV-2 SARS-COV-2 infection Secondary objective Secondary objectives sequential design Sodium chloride SOFA Study protocol subject survival survival rate syndrome the placebo group treatment group Trial Trial registration ventilator-free day Ventilator-free days Volume were infected with COVID-19 [DOI] 10.1186/s13063-021-05118-7 PMC 바로가기 [Article Type] Study Protocol
Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children소아에서 가와사키병과 코로나19 관련 다기관 염증 증후군 사이의 표현형, 감수성, 자가면역 및 면역요법Immunology Published on 2021-02-262022-09-11 Journal: Frontiers in Immunology [Category] MERS, 변종, 진단, [키워드] addition ADE anti-cytokine antibody Antibody-dependent enhancement Antigen Atypical Autoimmune Autoimmunity Blood Group Cardiovascular events children Coagulopathy conditions convalescent stage coronavirus coronavirus disease Coronavirus disease-19 Corticosteroid Corticosteroids COVID-19 COVID-19 infection develop Diseases enemy Evolution FcγR Fever FOXP3 gastrointestinal symptoms genetic susceptibility Genetic variant growth factor HLA HLA-B HLA-DRB1 Host hosts human leukocyte antigen hyperinflammation identify IFNγ IL-10 IL-17A IL-6 Immunity Immunoglobulin Immunopathogenesis immunotherapies Immunotherapy Inflammatory interferon interleukin interleukin-6 Intravenous immunoglobulin IP-10 IVIG Kawasaki disease Know thyself lesions leukocyte locus lower expression Lymphadenopathy mass vaccination Mild MIS-C multisystem inflammatory syndrome in children pathogen Pathogenesis Patient phenotype Phenotypes physician physiological Precision PROTECT protective factor provided recognize regimen resulting reversal risk allele Severe COVID-19 Infection Shock shown signaling molecules similarity standard treatment Subtypes susceptibility susceptible Symptom syndrome T helper TGF-β Th17 the disease TLR Toll-like receptor transforming growth factor Treatment treatment regimen Treg vaccination Vasculitis [DOI] 10.3389/fimmu.2021.632890 PMC 바로가기 [Article Type] Immunology
The Clinical Course of COVID-19 Pneumonia in a 19-Year-Old Man on Intravenous Immunoglobulin Replacement Therapy for X-Linked AgammaglobulinemiaX-연관 무감마글로불린혈증에 대한 정맥 면역글로불린 대체 요법을 받은 19세 남성의 코로나19 폐렴 임상 경과Case Reports Published on 2021-02-222022-09-11 Journal: The American journal of case reports [Category] MERS, 진단, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission agammaglobulinemia Azithromycin bronchiectasis clinical Clinical course clinical evaluation complications coronavirus coronavirus disease Coronavirus disease 2019 cough Course COVID-19 COVID-19 pneumonia Critically ill critically ill patients diarrhea dose Fever hospital immune Immunity Immunoglobulin immunologically infected individual Infection intensive care intensive care unit admission Intravenous immunoglobulin IVIG Man management Mild Multiple Multiple studies no symptoms outcome outcomes oxygen oxygen supplementation Patient piperacillin piperacillin/tazobactam Pneumonia productive cough Prophylactic receiving replacement replacement therapy reported resolved respiratory SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe COVID-19 severity Shortness of breath Steroids suggested Symptom tazobactam therapy Treatment Variation weakened X-linked agammaglobulinemia XLA [DOI] 10.12659/AJCR.929447 PMC 바로가기 [Article Type] Case Reports
High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China2019년 중증 코로나바이러스 질환의 고용량 정맥 면역글로불린: 중국의 다기관 후향적 연구Clinical Trial Published on 2021-02-192022-08-13 Journal: Frontiers in Immunology [Category] MERS, 임상, 진단, [키워드] 28-day mortality 95% CI addition adjusted Administered Analysis benefit body weight case sery China Comorbidities Comorbidity conducted coronavirus disease Coronavirus disease 2019 COVID-19 Cox proportional hazard Cox proportional hazards regression model disease disease onset dose effective Effectiveness enrolled evaluate Evidence ferritin High-dose high-dose intravenous immunoglobulin high-dose IVIg IL-10 IL-6 Immunoglobulin immunomodulation Inflammatory marker inflammatory markers Intravenous immunoglobulin IVIG Kaplan-Meier curve less mortality rate multiple imputation normalization Patient primary endpoint Probability reduced Regression model reported Result Retrospective study severe COVID-19 severe COVID-19 patient severe COVID-19 patients standard care Standard therapy subgroup analysis treated Treatment Weighting [DOI] 10.3389/fimmu.2021.627844 PMC 바로가기 [Article Type] Clinical Trial
Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic ImplicationsIVIg 제제 내 항SARS-CoV-2 항체: 계절성 코로나바이러스와의 교차 반응성, 자연 자가면역 및 치료적 의미Immunology Published on 2021-02-172022-09-11 Journal: Frontiers in Immunology [Category] MERS, 진단, 치료기술, [키워드] antibodies antibodies to SARS-CoV-2 antibody Antigen antigenic epitopes antigenic peptide antigenic protein antigens autoantibody autoreactive antibodies autoreactive antibody autoreactivity Baxalta benefit calibrator common cold comparable condition conserved coronavirus Coronaviruses COVID-19 COVID-19 infection cross-react cross-reacting antibodies cross-reactive antibody cross-reactivity with COVID-19 cut-off defined Donor ELISA enzyme-linked immunosorbent enzyme-linked immunosorbent assay epitope Epitopes False positivity Flebogamma Germany healthy donors IgG antibody Immune-mediated immunodeficiency Immunoglobulin in-hospital mortality index individuals infected individual Innovation IVIG Lubeck natural Patient patients peptides positive Protective Protein receiving Recognition recognizing SARS-CoV-2 screened seasonal semi-quantitative serum significantly lower symptomatic T-cell T-cells tested therapy titers treated uninfected [DOI] 10.3389/fimmu.2021.627285 PMC 바로가기 [Article Type] Immunology
Successful treatment of two Japanese ESRD cases with severe COVID-19 pneumonia중증 코로나19 폐렴을 동반한 일본 ESRD 사례 2건의 성공적인 치료Case Reports Published on 2021-02-012022-09-11 Journal: CEN case reports [Category] MERS, SARS, 진단, 치료제, [키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory distress syndrome (ARDS) Admission anti-cytokine anti-cytokine therapy ARDS Clinical course cohort study coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 COVID-19 pneumonia Diabetic diabetic nephropathy disease distress effective End-stage renal disease End-stage renal disease (ESRD) ESRD exhibited Hemodialysis high mortality rate ICU Immunoglobulin indicate infected with COVID-19 intensive care intensive care unit Intravenous immunoglobulin Intravenous immunoglobulin (IVIG) IVIG Japanese Maintenance hemodialysis mechanical ventilation nephropathy novel Novel coronavirus novel coronavirus disease Patient patients renal renal disease respiratory distress Respiratory distress syndrome Severe COVID-19 pneumonia syndrome Tocilizumab treated Treatment were infected with COVID-19 [DOI] 10.1007/s13730-020-00512-7 PMC 바로가기 [Article Type] Case Reports